Description
West Pharmaceutical Services’ Hidden Edge: Over 90% Win Rates In New Biologics!
West Pharmaceutical Services reported second quarter 2026 results marked by strong top- and bottom-line growth, driven primarily by the execution of its strategic initiatives and operational improvements. Revenue rose to $872 million, representing a 13% organic increase year-over-year, while adjusted earnings per share increased 29% to $2.37. These outcomes exceeded management’s expectations despite challenges including a cyber incident and the divestiture of the SmartDose 3.5mL On-Body Delivery System, whose manufacturing and supply rights were transferred as planned on July 1. The Proprietary Products segment, constituting the majority of revenue, grew 16% organically. This growth was led by the Halo high-value primary (HVP) Components business, which expanded 18% organically and now represents 49% of total company revenues, up from 46% in the prior-year quarter.
